Why wouldn't CVI convert the warrants in 3 months time when the pps is at 10c after further positive clinical trial updates from VAXINIA, OASIS and Azer-Cel???? And you need to look at the R&D expenditure for 2024, the $4.6M specified isn't related to their expenditure for that financial year.
The FY23 receivable amount for $11.7 million has been impaired by $4.5 million in FY24 to recognise management’s conservative approach to the portion of the tax claim related to overseas expenditure.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |